SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.
A phase 2 trial of SI-B001, Cisplatin, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
Overview
SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. is a phase 2 interventional study registered as NCT05020457 by Sichuan Baili Pharmaceutical Co., Ltd., with 69 participants enrolled, started 2021-12-07 and due to reach its primary completion in 2025-12. Interventions recorded: SI-B001, AP or TP, Docetaxel. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares SI-B001, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialSI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer
Shares SI-B001, SystImmune / Sichuan Biokin, Non-small-cell lung cancer.
- TrialA Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC
Shares SI-B001, SystImmune / Sichuan Biokin, Docetaxel.
- TrialA Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU
Shares SystImmune / Sichuan Biokin, Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC
Shares SI-B001, SystImmune / Sichuan Biokin.
- TrialA Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
Shares SI-B001, SystImmune / Sichuan Biokin.
- TrialA Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Sq
Shares SI-B001, SystImmune / Sichuan Biokin.
- TrialA Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU
Shares SystImmune / Sichuan Biokin, Cisplatin, Small-cell lung cancer, Non-small-cell lung cancer.